Great work my friend. Found a couple typos in bold. Those were the only ones I found. Maybe you could edit since everyone will be copying your post? I'll post an edited version after your version. Again, fine work, already posted this several places. Thanks for taking the time to put it together.
Leronlimab, a late state drug developed by American pharmaceutical company Cytodyn, is BY FAR the most effective drug for treating COVID-19 patients.
Cytodyn today announced a patient at a leading Southern California hospital, who was treated for 4 days on other drugs, but ended up on life support, came off of life support, and is now healed, withing days after being treated with Leronlimab.
Two of the other Socal CV patients were removed from oxygen soon after who being administered Leronlimab.
4 out of 9 seriously ill Covid-19 patients who were treated with Leronlimab at a leading New York City hospital, were able to be taken off of their ventilators after only three days.
The immune function in all 9 of these seriously ill Covid-19 patients was fully restored after 7 days, while their cytokine storms were reduced between 70 and 90 percent.
The patients who improved greatly on Leronlimab had previously been treated, without success, on either hydroxychloride or remdesivir.
In other words, these 9 patients had better results after being treated with Leronlimab than they had after being treated with either hydroxychloride or remdesivir.
In over 800 patients who have been treated with Leronlimab for HIV and metastatic breast cancer over the past five years, there has not been one serious adverse event attributable to this drug.
In other words, other than some pain at the injection site--and the injection is only subcutaneous, the same as an insulin injection--there are virtually no side effects from Leronlimab.
Leronlimab is now in two FDA approved clinical trials for mild to moderate, and seriously ill, Covid-19 patients.
Cytodyn expects to have at least some results from these trials within 30 days.
For the good of the country, Leronlimab should be the treatment of choice for both mild to moderate and seriously ill CV patients.
<<edited version with corrections>>
Leronlimab, a late state drug developed by American pharmaceutical company Cytodyn, is BY FAR the most effective drug for treating COVID-19 patients.
Cytodyn today announced a patient at a leading Southern California hospital, who was treated for 4 days on other drugs, but ended up on life support, came off of life support, and is now healed, within days after being treated with Leronlimab.
Two of the other Socal CV patients were removed from oxygen soon after being administered Leronlimab.
4 out of 9 seriously ill Covid-19 patients who were treated with Leronlimab at a leading New York City hospital, were able to be taken off of their ventilators after only three days.
The immune function in all 9 of these seriously ill Covid-19 patients was fully restored after 7 days, while their cytokine storms were reduced between 70 and 90 percent.
The patients who improved greatly on Leronlimab had previously been treated, without success, on either hydroxychloride or remdesivir.
In other words, these 9 patients had better results after being treated with Leronlimab than they had after being treated with either hydroxychloride or remdesivir.
In over 800 patients who have been treated with Leronlimab for HIV and metastatic breast cancer over the past five years, there has not been one serious adverse event attributable to this drug.
In other words, other than some pain at the injection site--and the injection is only subcutaneous, the same as an insulin injection--there are virtually no side effects from Leronlimab.
Leronlimab is now in two FDA approved clinical trials for mild to moderate, and seriously ill, Covid-19 patients.
Cytodyn expects to have at least some results from these trials within 30 days.
For the good of the country, Leronlimab should be the treatment of choice for both mild to moderate and seriously ill CV patients.
Leronlimab, a late state drug developed by American pharmaceutical company Cytodyn, is BY FAR the most effective drug for treating COVID-19 patients.
Cytodyn today announced a patient at a leading Southern California hospital, who was treated for 4 days on other drugs, but ended up on life support, came off of life support, and is now healed, withing days after being treated with Leronlimab.
Two of the other Socal CV patients were removed from oxygen soon after who being administered Leronlimab.
4 out of 9 seriously ill Covid-19 patients who were treated with Leronlimab at a leading New York City hospital, were able to be taken off of their ventilators after only three days.
The immune function in all 9 of these seriously ill Covid-19 patients was fully restored after 7 days, while their cytokine storms were reduced between 70 and 90 percent.
The patients who improved greatly on Leronlimab had previously been treated, without success, on either hydroxychloride or remdesivir.
In other words, these 9 patients had better results after being treated with Leronlimab than they had after being treated with either hydroxychloride or remdesivir.
In over 800 patients who have been treated with Leronlimab for HIV and metastatic breast cancer over the past five years, there has not been one serious adverse event attributable to this drug.
In other words, other than some pain at the injection site--and the injection is only subcutaneous, the same as an insulin injection--there are virtually no side effects from Leronlimab.
Leronlimab is now in two FDA approved clinical trials for mild to moderate, and seriously ill, Covid-19 patients.
Cytodyn expects to have at least some results from these trials within 30 days.
For the good of the country, Leronlimab should be the treatment of choice for both mild to moderate and seriously ill CV patients.
<<edited version with corrections>>
Leronlimab, a late state drug developed by American pharmaceutical company Cytodyn, is BY FAR the most effective drug for treating COVID-19 patients.
Cytodyn today announced a patient at a leading Southern California hospital, who was treated for 4 days on other drugs, but ended up on life support, came off of life support, and is now healed, within days after being treated with Leronlimab.
Two of the other Socal CV patients were removed from oxygen soon after being administered Leronlimab.
4 out of 9 seriously ill Covid-19 patients who were treated with Leronlimab at a leading New York City hospital, were able to be taken off of their ventilators after only three days.
The immune function in all 9 of these seriously ill Covid-19 patients was fully restored after 7 days, while their cytokine storms were reduced between 70 and 90 percent.
The patients who improved greatly on Leronlimab had previously been treated, without success, on either hydroxychloride or remdesivir.
In other words, these 9 patients had better results after being treated with Leronlimab than they had after being treated with either hydroxychloride or remdesivir.
In over 800 patients who have been treated with Leronlimab for HIV and metastatic breast cancer over the past five years, there has not been one serious adverse event attributable to this drug.
In other words, other than some pain at the injection site--and the injection is only subcutaneous, the same as an insulin injection--there are virtually no side effects from Leronlimab.
Leronlimab is now in two FDA approved clinical trials for mild to moderate, and seriously ill, Covid-19 patients.
Cytodyn expects to have at least some results from these trials within 30 days.
For the good of the country, Leronlimab should be the treatment of choice for both mild to moderate and seriously ill CV patients.
